Latest news with #DeepikaJalota
Yahoo
23-05-2025
- Business
- Yahoo
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. ('PMV Pharma'; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Tuesday, May 27, 2025Time: 11:30 AM EDT Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025Time: 3:45 PM EDT A live audio webcast of the events will be available online at Events & Presentations. An archived replay of PMV Pharma's presentations will be available for 90 days following the webcast at Events & Presentations. About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit Investors Contact:Tim SmithSenior Vice President, Head of Corporate Development and Investor Relationsinvestors@ Media Contact:Kathy VincentGreig Communicationskathy@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-02-2025
- Business
- Yahoo
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: Wednesday, February 12, 2025Time: 12:40 PM EST TD Cowen 45th Annual Health Care Conference Date: Tuesday, March 4, 2025Time: 3:10 PM EST A live audio webcast of the events will be available online at Events & Presentations. An archived replay of the events will be available for 90 days following the webcast at Events & Presentations. About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit Investors Contact:Tim SmithSenior Vice President, Head of Corporate Development and Investor Relationsinvestors@ Media Contact:Kathy VincentGreig Communicationskathy@ in to access your portfolio
